Discussion  by unknown
Charitos et al Acquired Cardiovascular Disease
A
C
Dendorsed by the Society for Cardiovascular Angiography and Interventions and
the Society of Thoracic Surgeons. Circulation. 2006;114:e84-231.
12. Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH,
Grunkemeier GL, et al. Guidelines for reporting mortality and morbidity after
cardiac valve interventions. Eur J Cardiothorac Surg. 2008;135:732-8.
13. Hess KR, Serachitopol DM, BrownBW.Hazard function estimators: a simulation
study. Stat Med. 1999;18:3075-88.
14. M€uller HG, Wang JL. Hazard rate estimation under random censoring with vary-
ing kernels and bandwidths. Biometrics. 1994;50:61-76.
15. Charitos EI, Stierle U, Hanke T, Schmidtke C, Sievers H-H, Richardt D. Long-
term results of 203 young and middle-aged patients with more than 10 years of
follow-up after the original subcoronary Ross operation. Ann Thorac Surg.
2012;93:495-502.
16. Ross DN. Replacement of aortic and mitral valves with a pulmonary autograft.
Lancet. 1967;2:956-8.
17. Stelzer P. The Ross procedure: state of the art 2011. Semin Thorac Cardiovasc
Surg. 2011;23:115-23.
18. Kouchoukos NT. Should we still do the Ross operation in adults? Curr Opin Car-
diol. 2011;26:94-8.
19. Kouchoukos NT, Davila-Roman VG, Spray TL, Murphy SF, Perrillo JB. Re-
placement of the aortic root with a pulmonary autograft in children and young
adults with aortic-valve disease. N Engl J Med. 1994;330:1-6.
20. Kouchoukos NT, Masetti P, Nickerson NJ, Castner CF, Shannon WD, Davila-
Roman VG. The Ross procedure: long-term clinical and echocardiographic fol-
low-up. Ann Thorac Surg. 2004;78:773-81.
21. Stelzer P. Reoperation for dilatation of the pulmonary autograft after the Ross
procedure. J Thorac Cardiovasc Surg. 2002;124:417-8.
22. Klieverik LM, Takkenberg JJ, Bekkers JA, Roos-Hesselink JW, Witsenburg M,
Bogers AJ. The Ross operation: a Trojan horse?EurHeart J. 2007;28:1993-2000.
23. Takkenberg JJ, Klieverik LM, Schoof PH, van Suylen RJ, van Herwerden LA,
Zondervan PE, et al. The Ross procedure: a systematic review and meta-analysis.
Circulation. 2009;119:222-8.
24. Takkenberg JJ, Zondervan PE, van Herwerden LA. Progressive pulmonary auto-
graft root dilatation and failure after Ross procedure. Ann Thorac Surg. 1999;67:
551-3.
25. Yacoub MH, Klieverik LM, Melina G, Edwards SE, Sarathchandra P, Bogers AJ,
et al. An evaluation of the Ross operation in adults. J Heart Valve Dis. 2006;15:
531-9.
26. El-Hamamsy I, Eryigit Z, Stevens L-M, Sarang Z, George R, Clark L, et al. Long-
term outcomes after autograft versus homograft aortic root replacement in adults
with aortic valve disease: a randomised controlled trial. Lancet. 2010;376:524-31.
27. Stelzer P. Technique and results of the modified Ross procedure in aortic regur-
gitation versus aortic stenosis. Adv Cardiol. 2002;39:93-9.
28. Stelzer P, Weinrauch S, Tranbaugh RF. Ten years of experience with the modified
Ross procedure. J Thorac Cardiovasc Surg. 1998;115:1091-100.
29. Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O’Gara PT, et al.
ACC/AHA 2008 Guideline update on valvular heart disease: focused update on in-
fective endocarditis: a report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines endorsed by the Society of
CardiovascularAnesthesiologists, Society for CardiovascularAngiography and In-
terventions, and Society ofThoracicSurgeons. JAmColl Cardiol. 2008;52:676-85.
30. David TE, Omran A, Ivanov J, Armstrong S, de Sa MP, Sonnenberg B, et al. Di-
lation of the pulmonary autograft after the Ross procedure. J Thorac Cardiovasc
Surg. 2000;119:210-20.
31. David TE, Omran A,Webb G, Rakowski H, Armstrong S, Sun Z. Geometric mis-
match of the aortic and pulmonary roots causes aortic insufficiency after the Ross
procedure. J Thorac Cardiovasc Surg. 1996;112:1231-9.
32. David TE, Woo A, Armstrong S, Maganti M. When is the Ross operation a good
option to treat aortic valve disease? J Thorac Cardiovasc Surg. 2010;139:68-73.
33. Brown JW, Fehrenbacher JW, Ruzmetov M, Shahriari A, Miller J,
Turrentine MW. Ross root dilation in adult patients: is preoperative aortic insuf-
ficiency associated with increased late autograft reoperation? Ann Thorac Surg.
2011;92:74-81.
34. Brown JW, RuzmetovM, Rodefeld MD, Mahomed Y, Turrentine MW. Incidence
of and risk factors for pulmonary autograft dilation after Ross aortic valve re-
placement. Ann Thorac Surg. 2007;83:1781-7.
35. Ryan WH, Prince SL, Culica D, Herbert MA. The Ross procedure performed for
aortic insufficiency is associated with increased autograft reoperation. Ann
Thorac Surg. 2011;91:64-9.
36. Mokhles MM, Bogers AJJC, Takkenberg JJM. No Ross operation for patients
with aortic regurgitation? Ann Thorac Surg. 2011;92:1156-7.The Journal of Thoracic and Ca37. H€orer J, Stierle U, Bogers AJJC, Rein JG, Hetzer R, Sievers HH, et al. Re-inter-
ventions on the autograft and the homograft after the Ross operation in children.
Eur J Cardiothorac Surg. 2010;37:1008-14.
38. H€orer J, Hanke T, Stierle U, Takkenberg JJM, Bogers AJJC, Hemmer W, et al.
Homograft performance in children after the Ross operation. Ann Thorac Surg.
2009;88:609-15.
39. Stulak JM, Burkhart HM, Sundt TM III, Connolly HM, Suri RM, Schaff HV, et al.
Spectrum and outcome of reoperations after the Ross procedure. Circulation.
2010;122:1153-8.
40. Luciani GB, Favaro A, Casali G, Santini F, Mazzucco A. Reoperations
for aortic aneurysm after the Ross procedure. J Heart Valve Dis. 2005;14:
766-72.
41. Juthier F, Vincentelli A, Pinc¸on C, Banfi C, Ennezat PV, Marechaux S, et al. Re-
operation after the Ross procedure: incidence, management, and survival. Ann
Thorac Surg. 2012;93:598-604.
42. Bekkers JA, Klieverik LMA, Raap GB, Takkenberg JJM, Bogers AJJC. Aortic
root reoperations after pulmonary autograft implantation. J Thorac Cardiovasc
Surg. 2010;140:S58-63.
43. Pettersson GB, Subramanian S, Flynn M, Nowicki ER, Batizy LH, Svensson LG,
et al. Reoperations after the Ross procedure in adults: towards autograft-sparing/
Ross reversal. J Heart Valve Dis. 2011;20:425-32.
44. van Geldorp MWA, Jamieson WRE, Kappetein AP, Ye J, Fradet GJ,
Eijkemans MJC, et al. Patient outcome after aortic valve replacement with a me-
chanical or biological prosthesis: weighing lifetime anticoagulant-related event
risk against reoperation risk. J Thorac Cardiovasc Surg. 2009;137:881-6.
45. Puvimanasinghe JPA, Takkenberg JJM, Edwards MB, Eijkemans MJC,
Steyerberg EW, Van Herwerden LA, et al. Comparison of outcomes after aortic
valve replacement with a mechanical valve or a bioprosthesis using microsimu-
lation. Heart. 2004;90:1172-8.
46. Grunkemeier GL, Li HH, Naftel DC, Starr A, Rahimtoola SH. Long-term perfor-
mance of heart valve prostheses. Curr Probl Cardiol. 2000;25:73-154.
47. Treasure T, Hasan A, Yacoub M. Is there a risk in avoiding risk for younger pa-
tients with aortic valve disease? BMJ. 2011;342:d2466.
48. Takkenberg JJM. Invited commentary. Ann Thorac Surg. 2012;93:502.
49. Charitos EI, Stierle U, Sievers H-H. Letter by Charitos et al regarding article, ‘‘re-
operation of left heart valve bioprostheses according to age at implantation.’’Cir-
culation. 2012;125:e583.
50. Chan V, Malas T, Lapierre H, Boodhwani M, Lam B-K, Rubens FD, et al. Reop-
eration of left heart valve bioprostheses according to age at implantation. Circu-
lation. 2011;124:S75.
51. Chan V, Malas T, Lapierre H, Boodhwani M, Lam B-K, Rubens FD, et al. Re-
sponse to letter regarding article, ‘‘reoperation of left heart valve bioprostheses
according to age at implantation.’’ Circulation. 2012;125:e584.Discussion
Dr JosephA. Dearani (Rochester, Minn). I have no disclosures.
Congratulations on the remarkable results. One of our previous
AATS [American Association for Thoracic Surgery] presidents,
Dr Tirone David, has acknowledged in the literature that the
Ross procedure is a ‘‘complex operation and one should not be sur-
prised that reoperations are more complicated.’’ In contrast, stan-
dard aortic valve replacement is generally a straightforward
operation that most residents would be allowed to perform. The
Ross procedure in children is not controversial. In fact, it is the pro-
cedure of choice when aortic valve replacement is required. How-
ever, in adults, the low early mortality of isolated aortic valve
replacement and relative good durability of bioprostheses or low
incidence of thromboembolic complications with ‘‘point of
care’’ testing in mechanical valve replacements makes the Ross
procedure more controversial. My comments will focus on 3 as-
pects of your results in the adult age bracket, and I will ask 3 ques-
tions at the end.
First, at the initial glance, superior autograft durability with the
SC implantation techniquemight imply that this is the technique ofrdiovascular Surgery c Volume 144, Number 4 821
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Dchoice for Ross implantation. However, a more detailed consider-
ation of the results demonstrated a high early mortality of 8% to
9% for reoperation in this group. In addition, when reoperation
was necessary in the SC group, most required replacement and
none underwent valve-sparing root replacement. Thus, although
reoperation was less likely with the SC technique, the greater op-
erative mortality associated with reoperation might temper enthu-
siasm to apply it more frequently.
Second, the finding of the relatively high incidence of endocar-
ditis of either the autograft or homograft is eye opening, counter-
intuitive, and unexpected, particularly because some centers
believe the Ross is the preferred operation for the initial treatment
of aortic valve endocarditis. Although no obvious explanation is
present in your report, I wonder whether the homograft preserva-
tion and preparation techniques in Europe could have potentially
influenced the susceptibility to infection.
Finally, the cumulative number of reinterventions or reopera-
tion for any given patient in the Ross population can be numerous.
Your results will add to the abundant data reporting the reoperation
rates after the Ross procedure. However, the reoperation rates
alone do not reflect the valve disease that many Ross patients are
harboring but for which they have not yet required reoperation.
Although isolated biologic or mechanical aortic valve replace-
ment is not free of subsequent interventions, when they are re-
quired, it is more likely related to isolated aortic valve issues
and complexity, and the risk of reoperation is often less than that
after the Ross. With that said, your report today of low early mor-
tality for the Ross procedure and low early mortality with reoper-
ation and the excellent late survival make a persuasive argument
for more liberal application of the Ross procedure in the young
and in middle-age adults, particularly when surgical services are
centralized.
My questions are the following. First, what is the Ross implan-
tation technique of choice? Second, do you believe the Ross pro-
cedure is a legitimate contender in the current era of excellent
outcomes with minimally invasive aortic valve replacement? Fi-
nally, although not the focus of your review, do you have any echo-
cardiographic data about autograft or homograft abnormalities in
patients who are ‘‘on the way’’ to reoperation?
Thank you to the Association for the privilege of this discussion
and congratulations on the remarkable results.
Dr Charitos. Thank you very much. These are very pertinent
questions. The Ross technique of choice is more or less a matter
of debate. Obviously I am biased toward the SC technique. I
come from Luebeck; Professor Sievers has probably the most ex-
tensive experience with the SC technique. I do believe that the
Ross procedure should be performed with the SC technique.
This seems logical. We have now more than 600 patients with
a complete follow-up rate of 98%. We know exactly what happens
to all our patients. The SC technique seems to be technically more
demanding; one should know which items one should pay special
attention to and which to avoid during the procedure, but the SC
technique does provide more robust results.
Some surgeons might prefer other techniques, such as the root
replacement technique or root replacement with reinforcement.
Some prominent root replacement series have been published,
with very good results. However, in general and in the multicenter
Ross registry, the root replacement technique without822 The Journal of Thoracic and Cardiovascular Surgreinforcement has generally underperformed, and I think the
data are consistent that the SC provides the best and the most ro-
bust results in the long term.
Your second question has to do with minimally invasive aortic
valve replacement in this era. Minimally invasive aortic valve re-
placement does not offer many advantages for the 20-, 30-, or
35-year-old patient. Perhaps cosmetically; however, the problem
of valve choice in the patient who is 20 or 25 years old does not
depend on the type of surgical access.
The problem these patients face is mainly from the type of pros-
thesis. If one implants a biologic valve in a 20-year-old patient, one
will probably see the patient again in 5 to 7 years. However; a me-
chanical valve will change the patient’s lifestyle, and the patient
will face a certain lifetime risk of significant complications.
Thus, the type of surgical access for aortic valve replacement in
young patients I do not believe has a major effect for a young pa-
tient with aortic valve disease, other than, perhaps, cosmetic
implications.
And the third question?
Dr Dearani.Whether you have any information about echocar-
diographic data on the hemodynamic abnormalities in patients that
many have but who have not yet required reoperation.
Dr Charitos. This is also a very pertinent question. We do have
echocardiographic data. There are patients who have some auto-
graft or homograft dysfunction that might eventually require reop-
eration but who have, at least for now, not reached the indications
for reoperation. The indications for reoperation are much more
clear with the autograft and slightly more hazy for the homograft,
but certainly we had patients in the study with valve dysfunction at
risk of reoperation.
Dr Azhar Hossain (Miami, Fla). My question is regarding the
bicuspid valve in the young adult, say 20 years old, with severe re-
gurgitation.Would you recommend the Ross procedure for that pa-
tient? If so, what procedure would you choose, the classic Ross,
which is the SC, or the root replacement?
Dr Charitos. A bicuspid aortic valve is not a contraindication
for the Ross procedure. Patients with pure aortic regurgitation do
have a greater risk of reoperation; the hazard ratio is about 2.4
to 2.9. But we do not consider patients with a bicuspid aortic valve
to have a contraindication to the Ross procedure. Currently, I think
the tendency is to repair these valves, but certainly we do not re-
gard a bicuspid aortic valve as a contraindication for the Ross
procedure.
The choice of procedure is more or less surgeon specific. We
have found that if a center uses 1 specific technique, it usually
sticks to that technique. Whether the surgeon will perform addi-
tional interventions, for example, to stabilize the aortic annulus
or the sinotubular junction in patients with pure aortic insuffi-
ciency who have some malformation of the aortic root, this is
something one must decide in the operating room. But the choice
of technique is mostly surgeon specific.
Dr Hossain. Thus, in other words, you are not concerned that in
a bicuspid aortic valve, there is additional risk of root dilatation if
you do a root replacement as opposed to an SC procedure?
Dr Charitos. No. We have extensively studied the effects
of bicuspid aortic valve in terms of aortic insufficiency and dilata-
tion of the aortic root. We published these findings about 3 or 4
years ago. We have found no clinically significant difference inery c October 2012
Charitos et al Acquired Cardiovascular Disease
A
C
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patients with a bicuspid aortic valve, irrespective of the technique.
Dr Hossain. I was referring to the pulmonary autograft that you
are going to use in the aortic position. That has the same disease as
the native aortic root, which has been reported by many well-pub-
lished investigators. Thus, if you use a pulmonary autograft, which
has a tendency to undergo dilatation, would you still use root re-
placement, as opposed to the SC, in a Ross procedure, which is
the classic Ross?
Dr Charitos. I do not think there is much evidence that the pul-
monary autograft in the aortic position in a patient with a bicuspid
valve has a greater failure rate. There is only 1 report from the team
of Tirone David stating that in some patients with bicuspid aortic
valves there are some histologic abnormalities, but that is a very
long way to proving that if this patient has a pulmonary autograft
in the bicuspid aortic valve position, that the autograft will fail. If
one wants to determine whether in a patient with bicuspid aortic
valve the autograft fails to a greater extent, one must investigate
exactly that assumption. One cannot state that because we have
seen some histologic abnormalities in the pulmonary valve of
some bicuspid aortic valve patients, then implanting this pulmo-
nary autograft in the aortic position would be the cause of the fail-
ure. That is a very big leap.
We have extensively analyzed the effect of bicuspid valves and
we have seen no clinically significant influence of the bicuspid aor-
tic valve on the durability of the autograft.
Dr Andre Vincentelli (Lille, France). Congratulations for your
outstanding series. What was the proportion of patients receiving
the SC technique coming from Leubeck in your series?
Dr Charitos. I think I can say we contributed most of the pa-
tients treated with the SC technique. From the 750 patients in
the Ross registry treated with the SC technique, about 580 were
from Leubeck.
Dr Vincentelli. This experience seems to be quite unique in
Leubeck and the very good results with the SC technique that
you have reported remain hardly reproducible elsewhere. In our
series of 394 patients undergoing a Ross operation, we have
used the modified root inclusion with a Dacron Valsalva prostheses
in 69 patients since 2003. We had no reoperation with this tech-
nique that has become routinely used since April 2010 in our insti-
tution. Do you have such experience?
Dr Charitos.We have few patients with Dacron root inclusion
and 30 patients with the miniroot inclusion technique in the RossThe Journal of Thoracic and Caregistry. That was too small a population to analyze it separately.
Thus, we included the miniroot inclusion patients with the SC pa-
tients. Most of these patients with the SC technique were patients
in whom the noncoronary sinus was preserved. So it could be
considered is a root-preserving technique; the SC technique or
the miniroot technique is a type of native root-preserving
technique.
DrNicholas T. Kouchoukos (St. Louis, Mo). Just a follow-up to
Dr Dearani’s questions. Regarding the SC technique, you have
a large experience with this, and it is fairly clear that the failure
rates will be different between the SC technique and the root re-
placement technique, and he asked you about echocardiographic
follow-up. Have you seen increases in the degree of aortic regurgi-
tation with the SC technique in patients who have not yet required
reoperation, because this is an important consideration. My second
question relates to the techniques of preservation of the homograft.
Were different techniques used among the different institutions?
Were these available commercially or were they prepared in
your own hospital?
Dr Charitos. Regarding your first question, we recently pub-
lished our experience with 200 patients with more than 10 years
of follow-up, and we had complete echocardiographic data avail-
able. We follow-up every patient; we examine every patient, every
year. We have a complete follow-up rate of more than 98% in Lue-
beck, so we know exactly what happens to the patients.
In the SC technique, we have not seen this gradual increase in
the dimensions and aortic regurgitation one sees with the root re-
placement technique. When the SC technique fails, it is usually
abrupt and mostly due to isolated leaflet problems, cusp prolapse
or cusp tear, or endocarditis. Nevertheless, there are few patients
with moderate aortic regurgitation who might may require reoper-
ation in the future.
Regarding your second question, the evaluation of the homo-
graft is a very complex topic. There are many factors that could po-
tentially have an influence. The factors we have presented were
factors influencing, not the function of the homograft, but the in-
cidence of reoperation as an event. Drs Mokhles and Takkenberg
are analyzing the homograft data with the cooperation of Dr Black-
stone. We hope we will have some high-quality data and results on
the durability of the homograft and homograft function and the risk
for deterioration within this year.
But I just want to say that the evaluation of the homograft is
a very, very complex topic.rdiovascular Surgery c Volume 144, Number 4 823
